EPCAM and neoplasm: Transiently increased liver parameters were typically observed, which can be partially explained by catumaxomab binding to EpCAM+ bile duct cells and the release of cytokines.37 The transient decrease in the peripheral lymphocyte count might be the result of migration of lymphocytes into the tissue and possibly to the tumor, mediated by upregulation of adhesion molecules on white blood cells after antibody-mediated activation.38